%0 journal article
%@ 1420-682X
%A Liu, Y.,Niu, R.,Li, W.,Lin, J.,Stamm, C.,Steinhoff, G.,Ma, N.

%D 2019
%J Cellular and Molecular Life Sciences
%N 9
%P 1681-1695 
%R doi:10.1007/s00018-019-03019-2
%T Therapeutic potential of menstrual blood-derived endometrial stem cells in cardiac diseases
%U https://doi.org/10.1007/s00018-019-03019-2
9 
%X Despite significant developments in medical and surgical strategies, cardiac diseases remain the leading causes of morbidity and mortality worldwide. Numerous studies involving preclinical and clinical trials have confirmed that stem cell transplantation can help improve cardiac function and regenerate damaged cardiac tissue, and stem cells isolated from bone marrow, heart tissue, adipose tissue and umbilical cord are the primary candidates for transplantation. During the past decade, menstrual blood-derived endometrial stem cells (MenSCs) have gradually become a promising alternative for stem cell-based therapy due to their comprehensive advantages, which include their ability to be periodically and non-invasively collected, their abundant source material, their ability to be regularly donated, their superior proliferative capacity and their ability to be used for autologous transplantation. MenSCs have shown positive therapeutic potential for the treatment of various diseases. Therefore, aside from a brief introduction of the biological characteristics of MenSCs, this review focuses on the progress being made in evaluating the functional improvement of damaged cardiac tissue after MenSC transplantation through preclinical and clinical studies. Based on published reports, we conclude that the paracrine effect, transdifferentiation and immunomodulation by MenSC promote both regeneration of damaged myocardium and improvement of cardiac function.